Conference Speakers

Bastian Brocks

Sales Manager - Nonwoven, SAUERESSIG Surfaces

BIOGRAPHY

Bastion Brocks is a seasoned sales and service professional in the nonwoven and industrial equipment sectors, currently serving as Sales Manager for the nonwoven industry at SAUERESSIG Group since 2021. He brings extensive experience in technical sales, service management, and product solutions, having previously held leadership roles at EMIS Electrics GmbH as Head of Service (2017–2021) and at Andritz Küsters GmbH, where he advanced from Service Supervisor to Sales Manager Rolls & Rebuilds over nearly a decade (2008–2017).

Trained as a Mechatronics Technician at Andritz Küsters GmbH and Berufskolleg Uerdingen, he combines strong technical expertise with strategic sales and service leadership to drive customer success across the nonwoven and industrial markets.

---

Advances in 3D Embossing & Aperturing Technologies for High-Performance Nonwovens in Hygiene Applications

Three-dimensional (3D) surface structuring of nonwovens—through embossing and aperturing—is an increasingly vital process for enhancing the functional performance of hygiene products. This paper presents a comprehensive review of current methodologies employed in the creation of structured nonwoven substrates, including thermal, hydroentanglement, ultrasonic, and mechanical techniques. These processes play a critical role in optimizing fluid management, improving dermal interaction, and enhancing air permeability in hygiene applications.

A central focus is placed on recent advancements in integrated roller-based systems, such as the VoluMAX� technology, which enable simultaneous embossing and aperturing at high line speeds. The study discusses key engineering challenges in process design, including thermal control, web tension management, pattern precision, and the effects of anisotropy on final material properties.

Emerging trends are also examined, such as the drive toward basis weight reduction without compromising performance, multilayer lamination strategies, and the development of advanced trial configurations